Author Letsch, Anne

• 2012 | Conference Abstract
  ​ ​Genome Wide DNA Methylation Analysis of Patients with Myelodysplastic Syndrome and Isolated Deletion (5q) Reveals Characteristic Methylation Profiles in Low and Intermediate-1 Risk Groups​
  Reinwald, M.; Nowak, D.; Platzbecker, U.; Giagounidis, A. A. N.; Goetze, K. S.; Ottmann, O. G. & Haase, D. et al.​ (2012)
  Blood, 120(21) ​54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)​, Atlanta, GA.
  Washington​: Amer Soc Hematology.
  ​Details  WoS 

• 2013 | Conference Abstract
  ​ ​TP53 mutations in patients with myelodysplastic syndrome and isolated deletion (5q) treated with lenalidomide: Results from the German Le-Mon-5 trial​
  Mossner, M.; Platzbecker, U.; Giagounidis, A. A. N.; Goetze, K.; Letsch, A.; Haase, D. & Schlenk, R. F. et al.​ (2013)
  Leukemia Research, 37 
  Oxford​: Pergamon-elsevier Science Ltd.
  ​Details  WoS 

• 2013 | Conference Abstract
  ​ ​Did the prognosis of MDS patients improve during the last 30 years?​
  Neukirchen, J.; Nachtkamp, K.; Pfeilstoecker, M.; Valent, P.; Stauder, R.; Blum, S. & Luebbert, M. et al.​ (2013)
  Leukemia Research, 37 
  Oxford​: Pergamon-elsevier Science Ltd.
  ​Details  WoS 

• 2013 | Conference Abstract
  ​ ​454 next generation sequencing identifies TP53 mutations in patients with myelodysplastic syndrome and isolated deletion (5q): Results from the German Le-Mon-5 trial​
  Mossner, M.; Nowak, D.; Platzbecker, U.; Giagounidis, A. A. N.; Goetze, K.; Letsch, A. & Haase, D. et al.​ (2013)
  Onkologie, 36 
  Basel​: Karger.
  ​Details  WoS 

• 2013 | Conference Abstract
  ​ ​Improvement of survival of MDS patients during the last 30 years​
  Neukirchen, J.; Stauder, R.; Pfeilstoecker, M.; Blum, S.; Haase, D.; Luebbert, M. & Hofmann, W.-K. et al.​ (2013)
  Onkologie, 36 
  Basel​: Karger.
  ​Details  WoS 

• 2013 | Conference Abstract
  ​ ​Response and progression rate of patients with primary MDS and isolated del(5q), IPSS low/int1 under treatment with lenalidomide​
  Germing, U.; Giagounidis, A. A. N.; Buesche, G.; Platzbecker, U.; Goetze, K.; Nolte, F. & Schlenk, R. F. et al.​ (2013)
  Leukemia Research, 37 
  Oxford​: Pergamon-elsevier Science Ltd.
  ​Details  WoS 

• 2014 | Conference Abstract
  ​ ​Impact of TP53 mutations on the clinical course in patients with MDS and isolated deletion 5(q) treated with Lenalidomid: results from the prospective Le-Mon-5 trial​
  Mossner, M.; Jann, J.-C.; Launinger-Loersch, E.; Nowak, D.; Platzbecker, U.; Giagounidis, A. A. N. & Goetze, K. et al.​ (2014)
  Oncology Research and Treatment, 37 
  Basel​: Karger.
  ​Details  WoS 

• 2014 | Conference Abstract
  ​ ​Clinical Impact of TP53 Mutations in Patients with MDS and Isolated Deletion 5(q) Treated with Lenalidomid: Results from the German Prospective Le-Mon-5 Trial​
  Mossner, M.; Jann, J. C.; Launiger-Loersch, E.; Nowak, D.; Platzbecker, U.; Giagounidis, A. A. N. & Goetze, K. S. et al.​ (2014)
  Blood, 124(21) 
  Washington​: Amer Soc Hematology.
  ​Details  WoS 

• 2014 | Journal Article | Letter Note
  ​ ​Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients​
  Platzbecker, U.; Al-Ali, H. K.; Gattermann, N.; Haase, D.; Janzen, V.; Krauter, J. & Goetze, K. et al.​ (2014) 
  Leukemia, 28(3) pp. 696​-698​.​ DOI: https://doi.org/10.1038/leu.2013.325 
  ​Details  DOI  PMID  PMC  WoS 

• 2015 | Conference Abstract
  ​ ​RESULTS OF THE MULTICENTER, PHASE II STUDY OF THE SAFETY OF LENALIDOMIDE MONOTHERAPY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH AN ISOLATED DEL(5Q)​
  Schuler, E.; Schemenau, J.; Giagounidis, A. A. N.; Haase, D.; Bueshce, G.; Platzbecker, U. & Nolte, F. et al.​ (2015)
  Leukemia Research, 39 ​13th International Symposium on Myelodysplastic Syndromes (MDS)​, Washington, DC.
  Oxford​: Pergamon-elsevier Science Ltd.
  ​Details  WoS 

Researcher

Sort

Items per Page